Biotage AB, formerly Pyrosequencing AB, is a Sweden-based company active within the biotechnology sector. The Company provides solutions in the areas of medicinal and analytical chemistry, process development and genetic analysis. Its business activities are divided into two segments: Discovery Chemistry and Biosystems. The Discovery Chemistry area supplies systems and consumables within pharmaceutical chemistry, including such areas as synthesis, work-up, purification and evaporation. Its solutions are marketed under the brand names of Initiator, Advancer, ISOLUTE, EVOLUTE, Isolera, FlashMaster and others. The Biosystems area offers systems for genetic analysis, mainly for the use in clinical research. It focuses its operations on two application areas: infectious disease and cancer research. The Biosystems’ activities are based on the Pyrosequencing technology, in which a sample’s deoxyribonucleic acid (DNA) sequences are read in real time with the help of sequencing by synthesis.
Third Wave is a growing leader in molecular diagnostics, providing DNA and RNA analysis products to clinical, research, and agricultural customers. Our company is one of the only companies in the molecular diagnostics market with a unique chemistry,the functional backbone of any molecular test. We are commercializing this unique chemistry to capture opportunities in this growth market. We have 150-160 clinical testing customers and the list continues to grow. In the United States, we serve most major clinical laboratories that perform tests in the molecular diagnostics testing market. Third Wave has also established a strong presence in Japan. Our Invader® chemistry is well recognized and widely used. Our clinical diagnostic products are used by clinical testing laboratories to create tests for prognosis, diagnosis, and monitoring by physicians of individual patients. In addition to molecular diagnostics, we support world-renowned researchers looking to improve the identification and management of disease, as well as agricultural customers in plant and animal genetics and diagnostics. Third Wave's facilities include GMP manufacturing, product development, and customer and technical services. Third Wave has achieved ISO 13485:2003 certification, a stringent, globally recognized standard of quality management.
Tm Bioscience Corporation is a DNA-based Diagnostics company developing a suite of genetic tests. Tm Bioscience's product pipeline includes tests for genetic mutations related to human disease, pharmacogenetics, and infectious disease. Tm Bioscience has advanced proprietary technologies, including the Universal Array that markedly improves the speed, accuracy, flexibility, and cost of DNA-based genetic tests. These technologies have been incorporated into the Tag-It platform, a highly flexible platform system for the development of rapid, accurate and economical genetic tests.
A: EraGen was founded in 1994 as Sulfonics, Inc., a California corporation. It changed its name to EraGen Biosciences and was reincorporated in Delaware in 1999. In 2002 the company consolidated its operations from Florida to new facilities in Madison, Wisconsin. Q: How large is EraGen? A: EraGen is a relatively small corporation, currently employing over 40 individuals in Madison, Wisconsin. The company continues to grow and anticipates increasing the number of employees and manufacturing facilities over the next two years. Q: What are the company's goals? A: EraGen will continue efforts to drive value by developing quality products for essential molecular diagnostics, building long term partnerships with industry leaders and creating a best-in-class Company. Q: What are EraGen's proprietary technology and products? A: EraGen has two major product lines under the brand name MultiCode that are powered by the company's core patented chemistry technology, the expanded genetic alphabet. These product lines include a multiplexed quantitative chemistry for real-time analysis (MultiCode-RTx System) and a high throughput multiplexed array system (MultiCode-PLx System). Q: Who are EraGen's major partners? A: Notable relationships include Bayer HealthCare in the area of molecular diagnostics, a long standing partner with EraGen. EraGen technology is at the core of Bayer's Versant Line of Infectious Disease bDNA Diagnostic Tests. Recently the two companies co-developed an innovative cystic fibrosis test. In the life science research market, EraGen holds a close relationship with Promega Corporation, who is licensed to market and sell EraGen quantitative real-time chemistry and annalysis software under the PlexorÔ brand name. Q: What is the status of EraGen intellectual property? A: EraGen holds 12 issued U.S. Patents in the areas of nucleic acid chemistry, proteomics and drug synthesis.
Myriad Genetics, Inc. is a healthcare company focused on the development and marketing of molecular diagnostic and therapeutic products. The Company’s molecular diagnostic business focuses on the analysis of genes and their alterations to assess an individual’s risk for developing disease later in life (predictive medicine) and to assess a patient’s risk of disease progression, disease recurrence, drug toxicity, and drug response (personalized medicine). As of June 30, 2008, the Company had launched five commercial molecular diagnostic products, including both predictive medicine and personalized medicine products. Its commercial molecular diagnostic products include BRACAnalysis, COLARIS, COLARIS AP, MELARIS and THERAGUIDE 5-FU. It markets these products through its own person sales force in the United States and it has entered into marketing collaborations with other organizations in selected foreign countries. On April 10, 2008, the Company acquired NaturNorth Technologies, LLC. (Source: 10-K)
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory